Francis Hondal
Francis Hondal's purchase track record
How the stock did after each of Francis Hondal's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/1/2025 | EQH | $5K | -11.2% | -9.8% | +11.6% |
| 11/21/2025 | BBWI | $50K | +65.5% | +20.6% | +13.2% |
| 8/12/2025 | EQH | $5K | -18.1% | -16.3% | +7.7% |
| 6/9/2025 | EQH | $5K | -2.0% | -14.7% | +14.0% |
| 3/12/2025 | EQH | $4K | +4.7% | +3.6% | +16.7% |
| 12/3/2024 | EQH | $4K | +8.0% | +13.8% | -1.3% |
| 8/13/2024 | EQH | $4K | +25.4% | +39.5% | +11.7% |
| 6/10/2024 | EQH | $4K | -1.0% | +16.4% | +12.9% |
| 3/4/2024 | EQH | $4K | +23.6% | +25.1% | +7.8% |
| 12/4/2023 | EQH | $4K | +4.4% | +29.0% | +15.6% |
| 8/14/2023 | EQH | $2K | -6.1% | +22.4% | +11.8% |
| 6/12/2023 | EQH | $2K | +8.6% | +25.7% | +6.5% |
| 3/6/2023 | EQH | $2K | -18.9% | -8.2% | +11.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
EQH to Announce Q3 2026 Results; Analysts Examine Fee‑Based Mix and Index Exit. Equitable Holdings has scheduled its third‑quarter 2026 earnings announcement. Recent analysis looks at how a shift toward fee‑based services could affect the company’s earnings mix, and whether the removal of an index and changes in asset‑management turnover might influence its outlook. These factors are being evaluated as the market awaits the upcoming results.
Transaction History
| BBWI | ▲ Buy | Grant | 7,970 | $0 | 6/11/2026 | View on chart |
| EQH | ▲ Buy | Grant | 4,400 | $185K | 5/20/2026 | View on chart |
| EQH | ▲ Buy | Open Market | 104 | $5K | 12/1/2025 | View on chart |
| BBWI | ▲ Buy | Open Market | 3,343 | $50K | 11/21/2025 | View on chart |
| EQH | ▲ Buy | Open Market | 92 | $5K | 8/12/2025 | View on chart |
| EQH | ▲ Buy | Open Market | 88 | $5K | 6/9/2025 | View on chart |
| BBWI | ▲ Buy | Grant | 5,641 | $0 | 6/5/2025 | View on chart |
| EQH | ▲ Buy | Grant | 3,393 | $0 | 5/21/2025 | View on chart |
| EQH | ▲ Buy | Open Market | 85 | $4K | 3/12/2025 | View on chart |
| EQH | ▲ Buy | Open Market | 89 | $4K | 12/3/2024 | View on chart |
| EQH | ▲ Buy | Open Market | 109 | $4K | 8/13/2024 | View on chart |
| BBWI | ▲ Buy | Grant | 3,844 | $0 | 6/27/2024 | View on chart |
| EQH | ▲ Buy | Open Market | 104 | $4K | 6/10/2024 | View on chart |
| EQH | ▲ Buy | Grant | 4,306 | $0 | 5/22/2024 | View on chart |
| EQH | ▲ Buy | Open Market | 112 | $4K | 3/4/2024 | View on chart |
| EQH | ▲ Buy | Open Market | 123 | $4K | 12/4/2023 | View on chart |
| EQH | ▲ Buy | Open Market | 84 | $2K | 8/14/2023 | View on chart |
| EQH | ▲ Buy | Open Market | 89 | $2K | 6/12/2023 | View on chart |
| BBWI | ▲ Buy | Grant | 3,572 | $0 | 6/8/2023 | View on chart |
| EQH | ▲ Buy | Grant | 6,473 | $0 | 5/24/2023 | View on chart |
| EQH | ▲ Buy | Open Market | 66 | $2K | 3/6/2023 | View on chart |
| EQH | ▲ Buy | Grant | 5,770 | $0 | 5/19/2022 | View on chart |
| BBWI | ▲ Buy | Grant | 3,091 | $0 | 5/12/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
BBWI shares jump 8.7% amid product innovation news
Bath & Body Works stock rose 8.7% recently, a move linked to its push into sensitive-skin products and broader product innovation. This strategy aims to support pricing as consumers look for value. The company also has a low P/E ratio of 4.5, which some analysts view as undervalued, though questions remain about its long-term outlook.
BBWI shares jump 8.7% amid product innovation news. Bath & Body Works stock rose 8.7% recently, a move linked to its push into sensitive-skin products and broader product innovation. This strategy aims to support pricing as consumers look for value. The company also has a low P/E ratio of 4.5, which some analysts view as undervalued, though questions remain about its long-term outlook.